维贝格龙(vibegron)中文说明书：适应症、用法用量、剂量调整、不良反应、注意事项

Vibegron was developed by Japan's Sumitomo Pharmaceuticals and is the world's first β3 adrenergic receptor agonist approved for the treatment of patients with overactive bladder (and benign prostatic hyperplasia (BPH)). The drug was released in 202 It was approved by the US FDA on December 23, 2019.

Indications of vibegron

Overactive bladder

Vibegron is mainly used to treat overactive bladder symptoms of urge urinary incontinence, urinary urgency and frequency in adults.

Vibegron usage and dosage

1. Recommended dose

Take 75 mg of vibegron orally once a day.

2. Administration

Swallow the entire tablet with or without food. Alternatively, you can crush the tablet and mix it with water. Mix approximately 15 mL of applesauce and take immediately with a glass of water.

Recommended article:

Vibegron dosage adjustment

1. Hepatic impairment

Mild to moderate liver impairment (Child-Pugh Class A and B). No dose adjustment is required for Vibegeron; it has not been studied in severe hepatic impairment (Child-Pugh Class C) and its use is not recommended.

2. Renal Impairment

Mild, moderate, or severe renal insufficiency (eGFR15 to <90mL/min/1.73m2). ; /h2>

Adverse reactions (≥2%)

Symptoms such as headache, urinary tract infection, nasopharyngitis, diarrhea, nausea, and upper respiratory tract infection may occur during treatment with vibegron.

Recommended articles:

Precautions for vibegron< /h2>

Urinary Retention

Vibegron may cause urinary retention, and patients with bladder outlet obstruction and those taking concomitant muscarinic antagonists to treat overactive bladder should be monitored for symptoms and signs. If urinary retention occurs, Vibegron should be discontinued.